CONTACT
+91 80 2808 2808
info@biocon.com
Inside banner
Biocon  /  News  /  Press Releases

PRESS RELEASES

2025

Biocon Biologics Secures Market Entry Date for Yesafili™, an Interchangeable Biosimilar to Eylea®, in the U.S.
Apr 15, 2025
Biocon Biologics Announces U.S. FDA Approval for Jobevne™, Biosimilar Bevacizumab, Expanding Its Oncology Portfolio
Apr 10, 2025
Biocon Biologics Announces Positive Results from Phase 3 Study of Yesintek™ Biosimilar to Ustekinumab for Chronic Plaque Psoriasis
Mar 07, 2025
Biocon Biologics and Civica, Inc. Collaborate to Expand Insulin Aspart Access in the United States
Mar 06, 2025
Biocon Pharma Limited Secures U.S. FDA Approvals for Lenalidomide and Dasatinib
Mar 04, 2025
Biocon Academy Conducts its 9th Graduation Day
Mar 04, 2025
Biocon Foundation Marks 20 Years of Transforming Lives Through Impactful Social Initiatives
Feb 28, 2025
Biocon Limited launches its Glucagon-like peptide-1 (GLP -1), Liraglutide, in the United Kingdom
Feb 28, 2025
Biocon Biologics Launches Yesintek™ (ustekinumab-kfce) Biosimilar to Stelara® in the United States
Feb 24, 2025
Biocon Foundation Dedicates Metro Pillars Public Art Project to ‘Everyday Champions’ of Bengaluru
Feb 11, 2025
Equillium Inc. and Biocon Limited Announce Positive Data from Phase 2 Study Evaluating Itolizumab in Patients with Moderate to Severe Ulcerative Colitis
Feb 06, 2025
Biocon Q3FY25 Revenue at Rs 3,856 Cr, Up 7%# EBITDA at Rs 787 Cr, Up 16%#; Net Profit at Rs 25 Cr
Jan 30, 2025
Biocon’s S&P Global ESG Score Improves to 69 for 2024
Jan 27, 2025
Biocon Biologics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Jan 09, 2025
Biocon Biologics Completes One Year as an Integrated Global Biosimilars Enterprise
Jan 07, 2025

2024

Kiran Mazumdar-Shaw Honored by ISQ with ‘Jamsetji Tata Award’ for Pioneering Biosciences Movement in India
Dec 14, 2024
Biocon Biologics Recognized as Asia IP Elite for 2024 by IAM, Cementing Leadership in Intellectual Property Excellence
Dec 11, 2024
Biocon Celebrates 46th Founder’s Day with Anthem Launch, Walkathon, Leadership Talk and Experience Center Inauguration
Nov 29, 2024
Biocon Biologics Supports Diabetes Africa to Drive Progress in Embedding Specialist Nurses in Diabetes Care in Ethiopia
Nov 27, 2024
Biocon Academy Achieves 100% Placement within 2.5 hours for Quality Control Analytical Program & Biocon Academy also Concludes 5th edition of MCADDI – 5-day Residential Program for Industry Experts
Nov 14, 2024
Biocon Q2FY25 Revenue at Rs 3,623 Cr, EBITDA at Rs 718 Cr
Oct 30, 2024
Biocon Continues to be Among Science Magazine’s Top 10 Global Employers List
Oct 28, 2024
Biocon Foundation Honored with ‘Doing Good for Bharat Awards 2024’ in ‘Healthcare Category’ for ‘eLAJ Smart Clinics’ by the CSR Box
Oct 25, 2024
Biocon Biologics Announces Results of Aflibercept Switching Study at American Academy of Ophthalmology Annual Meeting
Oct 23, 2024
Biocon Biologics’ Commissioned Report Highlights Pathways to Increase Adoption of Biosimilars in LMICs
Oct 08, 2024
Biocon Biologics Refinances USD 1.1 Billion (INR 93,468 million) Long Term Debt through USD Bonds and New Syndicated Facility
Oct 03, 2024
Biocon Limited partners with Tabuk Pharmaceuticals to commercialize its Glucagon-like peptide-1 (GLP -1) products in the Middle East region
Sep 26, 2024
Biocon Biologics Announces New Dermatology Data to Be Presented at EADV Congress 2024
Sep 25, 2024
Biocon Biologics Secures Market Entry for Bmab 1200, a Proposed Biosimilar to Stelara®, in Europe, UK, Canada, and Japan
Aug 29, 2024
Biocon Q1FY25 Revenue up 30% at Rs 4,567 Cr EBITDA up 117% at Rs 1,755 Cr Net Profit at Rs 660 Cr
Aug 08, 2024
Biocon Foundation and IISc organize OCTF Conference on Artificial Intelligence in Oral Cancer
July 30, 2024
Biocon Foundation conducts awareness session in 14 Government Schools
Jun 06, 2024
Biocon Limited signs exclusive licensing and supply deal for the commercialization of Liraglutide in South Korea with Handok Inc.
May 24, 2024
Biocon Biologics Obtains U.S. FDA Approval for Biosimilar Aflibercept for Yesafili™. Enters U.S. Ophthalmology Market
May 21, 2024
Biocon Q4FY24 Revenue at Rs 3,966 Cr, EBITDA at Rs 964 Cr; Net Profit (before exceptional items) at Rs 144 Cr
May 16, 2024
Biocon Limited signs semi-exclusive distribution and supply deal for the commercialization of generic Saxenda® (Liraglutide) in Mexico with Medix
May 13, 2024
Biocon Limited signs an exclusive licensing and supply agreement for generic Ozempic (Semaglutide) commercialization in Brazil with Biomm S.A.
Apr 17, 2024
Biocon is the first generics company to obtain approval for diabetes drug, Liraglutide, in the U.K.
Mar 27, 2024
Biocon Biologics Enters a Long-term Commercial Collaboration with Eris Lifesciences to Expand Patient Access in India
Mar 14, 2024
Biocon Biologics Secures US Market Entry Date for Bmab 1200, a Proposed Biosimilar to Stelara®
Feb 29, 2024
Biocon Included in S&P Global Sustainability Yearbook 2024
Feb 20, 2024
Biocon Biologics Partners with Sandoz Australia for Biosimilars Trastuzumab and Bevacizumab
Feb 09, 2024
Biocon Q3FY24 Revenue at Rs 4,519 Cr, Up 50%; Biosimilars Up 65%; Research Services Up 9%; EBITDA at Rs 1,492 Cr, Up 106%; Net Profit at Rs 660 Cr Pre-Paid USD 200 Mn towards Debt Reduction
Feb 08, 2024
Oral Cancer Task Force's Consensus Guidelines for Head & Neck Cancer Recognized Among 13 Worldwide Clinical Practice Guidelines
Feb 05, 2024

2023

Biocon Biologics Partners with Sandoz for the Distribution of “Adalimumab BS Subcutaneous Injection [FKB]” in Japan
Dec 22, 2023
Biocon Academy Conducts its 8th Graduation Day
Dec 19, 2023
Biocon Biologics Concludes Integration of Acquired Biosimilars Business in ~120 countries
Dec 18, 2023
Biocon Biologics Recognized as an Asia IP Elite for 2023, IPR Team adjudged as the Team of the Year
Dec 15, 2023
Biocon Biologics Successfully Completes Integration of Viatris’ Biosimilar Business in 31 Countries in Europe
Nov 30, 2023
Biocon Q2FY24 Revenue at Rs 3,620 Cr, Up 52%; Biosimilars Up 97%; Research Services Up 18% EBITDA at Rs 900 Cr, Up 68%; Core EBITDA at Rs 1,100 Cr, Up 35% Net Profit at Rs 126 Cr, Up 168%
Nov 10, 2023
EdelGive and Hurun India recognizes Kiran Mazumdar-Shaw as the Second most generous women philanthropist in India
Nov 9, 2023
Biocon Biologics Announces Divestment of Two Non-Core Branded Formulations – India Business Units
Nov 8, 2023
Biocon Ranked No. 8 Among Science Magazine’s Best Employers in Global Biotech and Pharma Sector
Oct 31, 2023
Kedar Upadhye Appointed as New CFO of Biocon Biologics Current CFO MB Chinappa to take on a Strategic Finance role at Biocon Group
Oct 19, 2023
Biocon Limited signs commercialization agreement with Juno Pharmaceuticals in Canada
Oct 6, 2023
Biocon Board Appoints Peter Bains as Group CEO
Sep 18, 2023
Kiran Mazumdar-Shaw appointed as member of the Court of Regents at the Royal College of Surgeons of Edinburgh
Sep 7, 2023
Biocon Biologics Continues to Expand Global Footprint, Completes Integration of Viatris Biosimilars’ Business In North America, Ahead of Schedule
Sep 6, 2023
Biocon Limited announces the acquisition of a manufacturing facility of Eywa Pharma Inc.
Sep 1, 2023
Biocon Q1FY24 Revenue at Rs 3,516 Cr, Up 59%; Biosimilars Up 106%; Research Services Up 25%
Aug 10, 2023
Biocon Foundation and Shakti Sustainable Energy Foundation organize Cities and Climate Action Workshop
Aug 9, 2023
Biocon Biologics Announces Key Leadership Appointments
Aug 4, 2023
Biocon Foundation Releases Second Edition of Consensus Guidelines for Head & Neck Cancer
Jul 27, 2023
Biocon Biologics Announces Positive CHMP Opinion for YESAFILI®, Biosimilar Aflibercept
Jul 24, 2023
Biocon Biologics Expands Footprint in Emerging Markets Takes Over the Commercialization of Biosimilars Business from Viatris in 70+ countries
Jul 5, 2023
After Five Years of Successful Experience Internationally, Biocon Biologics’ Hulio® Biosimilar to Humira®, Now Available in the United States
Jul 3, 2023
Biocon Group concluded the month-long sustainability initiatives commemorating ‘World Environment Day’ initiated with ‘Nature Positive’ Campaign
Jun 30, 2023
Biocon Q4FY23 Revenue at Rs 3,929 Cr, Up 59%; Biosimilars Up 114%; Research Services Up 31%
May 23, 2023
Biocon Biologics’ New mAbs Facility Receives EU GMP Certification for bBevacizumab
Apr 28, 2023
Serum & Biocon Biologics Agree to Restructure Equity Investment
Apr 25, 2023
Biocon Academy Conducted Graduation Ceremony For 185 Students across Four Programs
Apr 5, 2023
Biocon Awarded a Silver Medal by EcoVadis for its Sustainability Accomplishments
Apr 3, 2023
Biocon Biologics Wins the ‘ABEA : Bioprocessing Excellence in South Asia’ Award
Mar 28, 2023
Biocon Q3FY23 Revenue at Rs 3,020 Cr, Up 36%; Biosimilars Up 54%; Research Services Up 23%; Generics Up 18%
Feb 14, 2023
Biocon Foundation Wins the Prestigious ‘IHW Gold Award for Diseases Screening Initiative of the Year’ for 2022
Jan 24, 2023

2022

Biocon Biologics Recognized as a Company with Great Managers; Two Managers conferred with individual ‘Great Managers Award 2022’
Dec 22, 2022
Biocon Limited initiates clinical study of Itolizumab for Ulcerative Colitis in India
Dec 14, 2022
Shreehas Tambe Appointed as Managing Director & CEO of Biocon Biologics Limited
Dec 5, 2022
Biocon Biologics Completes Acquisition of Viatris’ Global Biosimilars Business
Nov 29, 2022
Biocon Limited enters into a commercialization agreement with Zentiva in Europe
Nov 23, 2022
Biocon Q2FY23 Revenue at Rs 2,384 Cr, Up 23%; Core EBITDA at Rs 816 Cr, Up 34% Gross R&D Spend at Rs 252 Crore, Up 52%
Nov 14, 2022
Biocon Biologics Features in the Prestigious ASIA IP ELITE List for 2022
Nov 11, 2022
Biocon Ranks at No. 8 in ‘Global Top Employers’ List by the U.S. Science Magazine  
Oct 31, 2022
Biocon Biologics Out-Licenses Two Biosimilar Assets to Yoshindo for Commercialization in Japan
Oct 17, 2022
Biocon Foundation Receives ‘Mahatma Award 2022 for Excellence in Social Good’
Oct 7, 2022
Kiran Mazumdar-Shaw Awarded with H.K. Firodia Lifetime Achievement Award 2022 for Excellence in Science & Technology
Sep 24, 2022
Biocon Foundation Celebrates the Spirit of ‘Har Ghar Tiranga’
Aug 13, 2022
Biocon Sdn. Bhd. Enters Malaysia Book of Records as the First & the Largest Integrated Insulin Manufacturing Facility
Aug 5, 2022
Biocon Q1FY23 Revenue at Rs 2,217 Cr, Up 23%; Net Profit at Rs 144 Cr, Up 71%; Core EBITDA at Rs 660 Cr Up 25%
Jul 27, 2022
University of Glasgow officially Opens Mazumdar Shaw Advance Research Centre
Jun 9, 2022
Biocon Biologics and Viatris Launch Abevmy® (bBevacizumab), Their Third Oncology Biosimilar, in Canada
May 19, 2022
Biocon Q4FY22 Revenue at Rs 2,476 Cr, Up 21%; Core EBITDA at Rs 815 Cr, Up 37% ; PBT(before Exceptional Items) at Rs 384 Cr, Up 9%
Apr 28, 2022
Biocon Biologics’ Insugen® Awarded a Three-Year Contract by Ministry of Health, Malaysia
Apr 26, 2022
Biocon Biologics’ Partner Receives Positive EU CHMP Opinion for Biosimilar Human Insulin for IV Infusion
Apr 1, 2022
University of Glasgow Names their Flagship Research Centre After John Shaw and Kiran Mazumdar-Shaw
Mar 29, 2022
Kiran Mazumdar-Shaw Elected as the Fellow of Royal Society of Edinburgh (RSE)
Mar 23, 2022
Biocon Biologics to Acquire Viatris’ Biosimilars Assets for up to USD 3.335 billion in Stock and Cash
Feb 28, 2022
Biocon Q3FY22 Revenue at Rs 2,223 Cr, Up 18%; EBITDA at Rs 537 Cr, Up 25%; Biosimilars Up 28% at Rs 981 Cr; Research Services Up 10% at Rs 641 Cr; Generics Up 7% at Rs 607 Cr
Jan 20, 2022

2021

Biocon Biologics* Partner Viatris Wins U.S. Court Decisions on Sanofi Appeals for Lantus® Device Patents
Dec 30, 2021
Clinical Study for Itolizumab in Lupus Nephritis Initiated in India, Post DCGI Approval
Dec 23, 2021
Biocon Ltd partners with Tabuk Pharmaceuticals to commercialise its speciality generic medicines in the Middle East
Dec 7, 2021
Biocon Enters Prestigious Dow Jones Sustainability Emerging Markets Index
Dec 1, 2021
Biocon Biologics and Viatris Announce Insulin Glargine (insulin glargine-yfgn) Injection Will Be Offered Through the Walgreens Prescription Savings Club
Nov 19, 2021
Biocon Biologics and Viatris Announce Launch of Interchangeable SEMGLEE® (insulin glargine-yfgn) Injection and Insulin Glargine (insulin glargine-yfgn) Injection
Nov 16, 2021
Biocon Biologics Collaborates with RSSDI to Expand Access to its Insulins for Children with Type 1 Diabetes on World Diabetes Day
Nov 15, 2021
Biocon Biologics and Viatris Announce Prime Therapeutics Prefers First-Ever Interchangeable Insulin Biosimilar Semglee® (insulin glargine-yfgn) Injection and Insulin Glargine (insulin glargine-yfgn) Injection on its National Formularies
Nov 4, 2021
Biocon Q2FY22 Revenue up 10% at Rs 1,945 Cr; EBITDA up 35% at Rs 551 Cr; Net Profit (before exceptional items) up 11% at Rs 188 Cr;
Oct 22, 2021
Biocon Biologics’ First-Ever Interchangeable Biosimilar Insulin Glargine, Co-Developed with Commercial Partner Viatris, Preferred on Express Scripts’ Largest Formulary in US
Oct 21, 2021
Biocon expands its Generic Formulations portfolio with the launch of Everolimus tablets in the US
Oct 4, 2021
Biocon Biologics and Serum Institute Life Sciences Announce Strategic Alliance
Sep 16, 2021
Biocon Biologics and Viatris Inc. Receive Historic Approval for First Interchangeable Biosimilar Semglee® (insulin glargine-yfgn injection) for the Treatment of Diabetes
Jul 29, 2021
Biocon Biologics Partners with Adagio Therapeutics to Advance Antibody for the Prevention and Treatment of COVID-19
Jul 26, 2021
Biocon Q1FY22 Revenue at Rs 1,808 Cr, Up 6%; EBITDA at Rs 437 Cr; Biosimilars Up 10 % at Rs 758 Cr; Research Services Up 41 % at Rs 595 Cr;
Jul 23, 2021
Biocon Q4FY21 Revenue at Rs 2,044 Cr, Up 26%; EBITDA at Rs 641 Cr; Up 68%
Apr 29, 2021
Biocon Biologics’ New Monoclonal Antibodies Manufacturing Facility Wins ISPE’s 2021 Facility of the Year Honorable Mention Award
Apr 28, 2021
Biocon Pharma partners with Libbs Farmaceutica to launch generic formulations in Brazil
Mar 29, 2021
Biocon Biologics Appoints Susheel Umesh as Chief Commercial Officer for Emerging Markets
Mar 2, 2021
Biocon Biologics Promotes Shreehas Tambe to Deputy Chief Executive Officer
Mar 1, 2021
Biocon Biologics and Viatris Inc. Receive CHMP Nod for Abevmy®, a Biosimilar to Avastin® (Bevacizumab)
Mar 1, 2021
Biocon Biologics Joins Hands with IDF in its Mission to Promote Diabetes Care, Prevention and effective Management Worldwide
Feb 16, 2021
Biocon Biologics to offer its Oncology Biosimilars through Cancer Access Partnership in over 30 countries
Feb 4, 2021
Biocon Q3FY21 Revenue at ₹ 1,879 Crore, Up 7%; EBITDA at ₹427 Crore; Net Profit at ₹169 Crore; Biosimilars up 11% at ₹769 Crore; Research Services up 13% at ₹585 Crore; Generics down 3% at ₹561 Crore
Jan 22, 2021
Professor Peter Piot Joins the Board of Biocon Biologics Limited as an Independent Director
Jan 21, 2021
Biocon Biologics Receives Rs 555 Cr (USD 75 Million) Capital Injection from ADQ
Jan 7, 2021

2020

Biocon expands generic formulations portfolio with the launch of Tacrolimus capsules in the US
Dec 28, 2020
Biocon Biologics signs an MoU with CSSC in Tanzania for Mission 10 cents
Dec 15, 2020
Biocon Biologics Receives USD 150 Million Capital Injection from Goldman Sachs
Nov 7, 2020
Biocon Ranked Among Top 5 Biotech Employers Globally
Oct 30, 2020
Biocon Q2FY21 Revenue at Rs 1,760 Cr, Up 10%; EBITDA at Rs 407 Cr; Net Profit (before exceptional item & discontinuing operations) at Rs 174 Cr; Generics Up 8% at Rs 599 Cr; Biosimilars Up 11% at Rs 676 Cr; Research Services Up 12% at Rs 520 Cr.
Oct 23, 2020
Biocon Foundation Signs MoU with Bangalore Metro to Contribute Towards Building Metro Station in Hebbagodi
Oct 8, 2020
Biocon Biologics to Roll Out ‘Mission 10 cents’ in Philippines; Signs MoU with 2 Municipal Governments & reach52 to enable Affordable Access to Quality Insulins
Sep 30, 2020
Biocon appoints Anupam Jindal as its Chief Financial Officer
Sep 22, 2020
Biocon Biologics and Mylan Announce Launch of Semglee™ (insulin glargine injection) in the U.S. to Expand Access for Patients Living with Diabetes
Aug 31, 2020
Tata Capital Growth Fund to Invest ~USD 30 million (Rs 225 Crore) in Biocon Biologics for an Equity Stake of 0.85% Deal Values Biocon Biologics at USD 3.5 Billion.
Jul 31, 2020
Biocon Q1FY21 Revenue at Rs 1,690 Cr, Up 14%; EBITDA at Rs 432 Cr; Net Profit (from continuing ops) at Rs 153 Cr Generics up 16% at Rs 599 Cr, Biosimilars up 19% at Rs 692 Cr
Jul 23, 2020
Biocon Biologics and Voluntis Join Hands for Global Collaboration on Digital Therapeutics for Insulins
Jul 21, 2020
Biocon Presented Insights into Clinical Study That Enabled DCGI Approval of Itolizumab for COVID-19
Jul 13, 2020
Biocon’s Breakthrough Drug Itolizumab Receives DCGI Nod for Emergency Use in Moderate to Severe COVID-19 Patients
Jul 11, 2020
Biocon Pharma and DKSH Collaborate to commercialize seven generic formulations in South East Asia markets
Jun 22, 2020
Biocon and Mylan Announce U.S. FDA Approval of Semglee™ (insulin glargine injection)
Jun 12, 2020
Kiran Mazumdar-Shaw Wins EY World Entrepreneur of the Year™ 2020 Award
Jun 5, 2020
Biocon’s* Partner Mylan Receives Favourable Ruling from U.S. PTAB on Sanofi’s Four Device Patents for Lantus® SoloSTAR®
Jun 1, 2020
Biocon Biologics Receives DCGI Approval for Emergency Use of CytoSorb® to Treat Critical COVID-19 Patients
May 27, 2020
Biocon Biologics Receives EU GMP Certification for Multiple Biosimilars Manufacturing Facilities in Bengaluru; Expands its Manufacturing Capacity
May 19, 2020
Biocon Earnings Q4FY20 Revenue Up 6% at Rs 1,644 Cr; EBITDA Down 11% at Rs 382 Cr; Net Profit Down 42% at Rs 123 Cr
May 14, 2020
Biocon and Mylan Launch Fulphila®, Biosimilar Pegfilgrastim, in Canada
Apr 28, 2020
Kiran Mazumdar-Shaw Recognized among World’s Top 20 Inspirational Leaders in Biopharmaceuticals in The Medicine Maker ‘Power List 2020’
Apr 27, 2020
Biocon and Mylan Launch Fulphila®, Biosimilar Pegfilgrastim, in Australia
Apr 14, 2020
Biocon & Biocon Biologics Ensuring Manufacturing of Life-Saving Medicines for Patients, Partners and Customers
Mar 27, 2020
Biocon & Mylan Win Patent Litigation Asserted by Sanofi for Insulin Glargine Device Patent in U.S.
Mar 11, 2020
U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon’s Proposed Biosimilar Bevacizumab for Review
Mar 9, 2020
Kiran Mazumdar-Shaw Named EY Entrepreneur of the Year India 2019
Feb 20, 2020
Biocon Q3FY20 Earnings Revenue at Rs 1,784 Cr, Up 14%; EBITDA at Rs 480 Cr, Up 18%; Net Profit (before exceptional item) at Rs 225 Cr, Up 6%
Jan 23, 2020
Kiran Mazumdar-Shaw Honoured with Order of Australia, Australia’s Highest Civilian Honour
Jan 18, 2020
True North to Invest Rs 536.25 Crore in Biocon Biologics for 2.44% Stake
Jan 6, 2020
Biocon Biologics Appoints M.B. Chinappa as Chief Financial Officer
Jan 6, 2020

2019

Biocon & Equillium Expand Exclusive Licensing Agreement for Itolizumab to Include Australia and New Zealand
Dec 12, 2019
Biocon Biologics Symposium on ‘100 years of Insulin – Delivering on Universal Access & Equitable Care’ Resonates Well with Leading KOLs at IDF Congress 2019
Dec 11, 2019
Biocon Biologics Takes Forward Its Mission to Unlock Universal Access to Insulins Globally
Dec 3, 2019
Siddharth Mittal Takes Over as CEO and Joint Managing Director of Biocon Limited
Dec 3, 2019
Biocon and Mylan Launch Trastuzumab Biosimilar, Ogivri™ (trastuzumab-dkst), in the U.S.
Dec 2, 2019
USFDA Approves Biocon’s sBLA for Pegfilgrastim New Manufacturing Facility
Nov 27, 2019
Kiran Mazumdar-Shaw Conferred with Lifetime Achievement Award by Indian Council of Medical Research
Nov 18, 2019
Biocon Features in the Prestigious ASIA IP ELITE List for the Fourth Consecutive Year
Nov 12, 2019
Biocon’s Biologics Drug Products Facility in Bengaluru Receives EIR from U.S. FDA
Nov 5, 2019
Biocon Moves Up to Rank No. 6 on Science Careers’ Top 20 Global Pharma & Biotech Employers List 2019
Oct 28, 2019
Biocon Q2FY20 Earnings Revenue at Rs 1,611 Cr, Up 17 %; EBITDA at Rs 441 Cr, Up 12%; Net Profit (excluding exceptional item) at Rs 189 Cr, Up 3%
Oct 23, 2019
Biocon Biologics & Just – Evotec Biologics Sign Licensing Deal for a Biosimilar Asset
Oct 10, 2019
Biocon and Mylan Launch First Insulin Glargine Biosimilar, Semglee®, in Australia
Oct 3, 2019
Kiran Mazumdar-Shaw Promises to Enable Universal Access to rh-Insulin by Reducing Prices to Less than 10 US cents /Day for LMICs
Sep 26, 2019
Biocon Biologics Expands its R&D Footprint Through Acquisition
Sep 24, 2019
Biocon Licenses Three Generic Formulation Products to China Medical System Holdings
Sep 12, 2019
Biocon’s Malaysia Insulin Glargine Manufacturing Facility Receives EU GMP Certification, Provides Fillip to its Capacity
Aug 22, 2019
Mylan and Biocon Launch First Trastuzumab Biosimilar, Ogivri™, in Australia
Aug 1, 2019
Biocon Q1FY20 Revenue Rs 1,490 Cr, Up 25%; EBITDA Up 51% at Rs 462 Cr; Net Profit (excluding exceptional item) Up 86% at Rs 223 Cr
Jul 25, 2019
Health Canada Approves Biocon and Mylan’s Ogivri™, the First Trastuzumab Biosimilar, for the Treatment of HER2-Positive Breast and Gastric Cancers
May 22, 2019
Biocon and Mylan to Present Final Overall Survival Data for OgivriTM(trastuzumab-dkst), a biosimilar to Herceptin®, at the American Society of Clinical Oncology (ASCO) Annual Meeting
May 16, 2019
Biocon Q4FY19 Revenue Rs 1,557 Cr, Up 26%; EBITDA Up 43% at Rs 431 Cr; Net Profit Up 64% at Rs 214 Cr FY19 Revenue Up 31% at Rs 5,659 Cr; Net Profit Up 143% at Rs 905 Cr
Apr 25, 2019
Kiran Mazumdar-Shaw Conferred With Honorary Doctorate from Deakin University, Australia
Mar 13, 2019
Biocon Appoints Dr. Christiane Hamacher as CEO Of Biocon Biologics India Limited
Mar 1, 2019
Kiran Mazumdar-Shaw elected as Member of the National Academy of Engineering, U.S.
Feb 8, 2019
Biocon Q3FY19 Earnings Revenue at Rs 1,566 Cr, Up 43%; Net Profit at Rs 217 Cr, Up 136% EBITDA at Rs 406 Cr, Up 59%
Jan 24, 2019

2018

Biocon Foundation Dedicates Rejuvenated Hebbagodi Lake and Children’s Park to the Community
Dec 2, 2018
Biocon Ranked 7th on Top Global Pharma & Biotech Employers List 2018
Oct 30, 2018
Biocon Q2FY19 Revenue at Rs 1,375 Cr, Up 35%; EBITDA at Rs 394 Cr, Up 69%; Net Profit at Rs 355 Cr; Net Profit (excluding exceptional income) at Rs 184 Cr; Up 167%
Oct 25, 2018
Biocon and Mylan Announce Positive CHMP Opinion for Ogivri®, Biosimilar Trastuzumab
Oct 19, 2018
Biocon and Mylan Announce Positive CHMP Opinion for Fulphila®, Biosimilar Pegfilgrastim
Sep 21, 2018
Biocon Q1FY19 Revenue Rs 1,193 Cr, Up 21%; EBITDA Up 25% at Rs 307 Cr; Net Profit Up 47% at Rs 120 Cr
Jul 26, 2018
Kiran Mazumdar-Shaw Elected Full-Term Member of the Board of Trustees of MIT, USA
Jun 28, 2018
U.S. FDA Approves Mylan and Biocon’s Fulphila™ (pegfilgrastim-jmdb), the First Biosimilar to Neulasta®
Jun 5, 2018
Tata Memorial Hospital Team Presents Biocon’s Nimotuzumab Study Results at ASCO Annual Meeting 2018
Jun 4, 2018
Mylan and Biocon to Present New Data at the American Society of Clinical Oncology (ASCO) Annual Meeting Reinforcing the Efficacy, Safety and Immunogenicity of Ogivri™, the first biosimilar for Herceptin®, approved by US FDA
Jun 2, 2018
Biocon Q4FY18 Revenue Rs 1,237 Cr, Up 27%; EBITDA Up 30% at Rs 300 Cr; Net Profit Up 2% at Rs 130 Cr
Apr 26, 2018
Kiran Mazumdar-Shaw #1 Business Captain in ‘The Medicine Maker 2018 Power List’
Apr 18, 2018
Mylan and Biocon Receive Approvals from the European Commission and TGA, Australia for Semglee™ Biosimilar Insulin Glargine
Mar 28, 2018
Mylan and Biocon Receive Positive CHMP Opinion for Semglee™, Biosimilar Insulin Glargine
Jan 29, 2018
Biocon Q3FY18 Revenue at Rs 1092 Crore; EBITDA at Rs 256 Crore; Net Profit at Rs 92 Crore
Jan 24, 2018
Biocon Announces Exclusive Global Collaboration with Sandoz on Next-Generation Biosimilars
Jan 18, 2018

2017

Biocon and Mylan’s Biosimilar Trastuzumab Receives Approval from ANVISA, Brazil Through Their Partner Libbs
Dec 29, 2017
U.S. FDA Approves Mylan and Biocon´s OgivriTM the First Biosimilar for Trastuzumab, for the Treatment of HER2­Positive Breast and Gastric Cancers
Dec 1, 2017
European Medicines Agency Accepts Marketing Authorization Applications for Mylan and Biocon´s Proposed Biosimilars Trastuzumab and Pegfilgrastim
Dec 1, 2017
Biocon Launches KRABEVA® − Biosimilar Bevacizumab for Treating Several Types of Cancer in India
Nov 23, 2017
Biocon Q2FY18 Revenues at Rs 1019 Crore; EBITDA at Rs 233 Crore; Net Profit at Rs 69 Crore
Oct 26, 2017
Biocon Ranked Among Top 10 Global Pharma & Biotech Employers
Oct 25, 2017
JDRF Supports Biocon Study of Novel, Fast-acting Oral Insulin Tregopil for Type 1 Diabetes Treatment
Sep 6, 2017
Biocon Reports Q1FY18 Revenue at Rs 988 Crore; EBITDA at Rs 246 Crore; Net Profit at Rs 81 Crore
Jul 27, 2017
FDA Oncologic Drugs Advisory Committee Unanimously Recommends Approval of Mylan and Biocon’s Proposed Biosimilar Trastuzumab
Jul 14, 2017
Mylan and Biocon Present Clinical Data on Insulin Glargine at the American Diabetes Association’s 77th Scientific Sessions
Jun 11, 2017
Biocon Appoints Ms. Pratima Rao as Mission Director of Biocon Foundation
Jun 5, 2017
Kiran Mazumdar Shaw Felicitated with ‘AWSM Award for Excellence 2017’ by The Feinstein Institute for Medical Research, USA
May 5, 2017
Biocon Q4 FY17 Revenue Rs 974 Cr; Net Profit Rs 127 Cr; FY17 Revenue at Rs 4,079 Cr; Net Profit at Rs 612 Cr
Apr 27, 2017
U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon’s Proposed Biosimilar Pegfilgrastim for Review
Feb 16, 2017
Biocon Foundation & Department of Medical, Health & Family Welfare, Govt. of Karnataka Collaborate to Set Up Smart eLAJ Clinics in Karnataka
Feb 7, 2017
Biocon Wins MYR 300 Million Contract for Insulin from MoH, Malaysia
Jan 25, 2017
Biocon Q3 FY17 Net Profit Up 65% at Rs 171 Crore Revenue Rises 32% at Rs 1092 Crore; EBITDA Increases 57% to Rs 324 Crore
Jan 24, 2017
U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon’s Proposed Biosimilar Trastuzumab
Jan 11, 2017

2016

Journal of the American Medical Association (JAMA) Publishes Mylan and Biocon’s Proposed Biosimilar Trastuzumab Phase 3 Data
Dec 27, 2016
Biocon Features in Asia IP Elite 2016 List
Dec 9, 2016
Biocon’s Novel Diabetes Education Initiative for Medical Practitioners ‘ABIDE’ Awarded by RSSDI
Nov 29, 2016
Biocon Collaborates with Healthcare Professionals for a Public Awareness Campaign on Diabetes Prevention & Management Across India
Nov 11, 2016
Mylan and Biocon Announce U.S. FDA Submission for Proposed Biosimilar Trastuzumab
Nov 8, 2016
Mylan and Biocon Announce Regulatory Submission for Insulin Glargine Accepted for Review by European Medicines Agency
Nov 3, 2016
Biocon Ranked Among Global Top Ten Biotech Employers; The only Asian Company to Feature in 2016 Rankings Biocon moves up to No. 9 from No. 13 last year
Oct 28, 2016
Biocon Q2 FY17 Revenue Up 21%; EBITDA Up 45%; Revenues at Rs 992 Crs.; EBITDA at Rs 277 Crs.; Net Profit at Rs 147 Crs.
Oct 20, 2016
Biocon Appoints Suresh Subramanian as Head of Branded Formulations (India) Business
Sep 19, 2016
Kiran Mazumdar Shaw Appointed ‘Knight of the Legion of Honour’ by the Government of France
Sep 1, 2016
Mylan & Biocon Announce Regulatory Submission for Proposed Biosimilar Pegfilgrastim Accepted for Review by European Medicines Agency
Jul 21, 2016
Biocon’s Insulin Glargine Launched in Japan
Jul 15, 2016
Biocon, Quark Announce Initiation of Pivotal Phase II/III Study of QPI-1007 in Rare Eye Disease in India
Jun 23, 2016
Mylan and Biocon to Present Phase 3 Trastuzumab Biosimilar Data at the American Society of Clinical Oncology (ASCO) Annual Meeting
Jun 4, 2016
Biocon’s Insulin Glargine Receives Regulatory Approval in Japan
May 28, 2016
Biocon Q4FY16 Net Profit at Rs 361 Cr Revenue Crosses Rs 1,000 Cr; Up 17% FY 16 Revenues up 14% at Rs 3,570 Cr Net Profit at Rs 896 Cr
Apr 26, 2016
Biocon Inks Co-Development & Commercialization Agreement with Lab PiSA for rh- Insulin in USA
Mar 17, 2016
Biocon Gets its First Generic Formulation Approval in EU; On Track to Launch Rosuvastatin Tablets in FY 17
Feb 15, 2016
Biocon Q3FY16 Net Profit Up 13% at Rs 103 Crore, EBITDA Increases 23% to Rs 209 Crore, Revenues at Rs 857 Crore, up by 10%
Jan 21, 2016
Biocon Announces Data from Key Studies for Insulin Tregopil
Jan 21, 2016

Know more
about us

>> Factsheet
>> Biocon Biologics
>> Annual Reports

WHO WE ARE
KEY THERAPEUTIC AREAS
PRODUCTS
Biocon Finance
FINANCIAL CALENDAR
RESPONSIBILITY

Report adverse event/ side effects and/or product complaints for Biocon products.


Click here to report adverse event/side effects/product complaints and/or submit medical queries for Biocon Biologics Limited & BBL Affiliate products.

Click here to report adverse event/side effects/product complaints and/or post medical queries for Biocon Limited, Biocon Pharma Limited, Biocon Pharma Inc., Biocon Pharma UK Limited, Biocon Pharma Malta Ltd and Biocon FZ LLC products.





* Safe Harbour | Privacy Policy | Terms of Use © 2025, Biocon. All Rights Reserved
Share
Leaving the Biocon site!

You are now leaving the Biocon website for a Biocon affiliate site or third party site that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Biocon affiliate sites and third party sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.

Agree >>